RTIOXA-43 |
| Katalog-Nr.GC71296 |
RTIOXA-43 ist ein Orexinrezeptoragonist mit EC50 von 24 nM und 24 nM für OX2- und OX1-Rezeptoren.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2832067-72-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
In adult (12 month) mice, peripheral injection of RTIOXA-43 improves wake time, reduced sleep time and sleep/wake fragmentation. In addition, RTIOXA-43 improves sleep/wake quality by decreasing the number of episodes and increasing the duration of these episodes[2].
References:
[1]. Yanan Zhang, et al. Arylsulfoxamides as orexin receptor agonists. WO2022187231A1.
[2]. Kotz, Catherine, et al. Small Molecule Orexin Agonists Enhance Physical Activity, Cognition and Sleep Quality in Aged Mice. Obesity; Silver Spring Vol. 29, (Dec 2021): 163.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *